PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome

Clinical Endocrinology

Volumn 82, Issue 5, 2015, Pages 670-677

  Choi, Sung Hee ^a   Lim, Soo ^a   Hong, Eun Shil ^a   Seo, Ji A ^b   Park, Cheol Young ^c   Noh, Jung Hyun ^d   Mok, Ji Oh ^e   Lee, Ki Young ^f   Park, Jong Sook ^g   Kim, Dae Jung ^h   Lee, Chang Beom ⁱ   Kim, Sung Rae ^j   Jang, Hak Chul ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Inje University   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Gachon University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Ajou University School of Medicine   (South Korea)

ⁱ Hanyang University   (South Korea)

^j The Catholic University of Korea College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; ADOLESCENT; AGED; ANALYSIS; BLOOD; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; GLUCOSE BLOOD LEVEL; LIFESTYLE; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926638987     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12580     Document Type: Article

References (25)

1. Eckel, R.H., Grundy, S.M., &, Zimmet, P.Z., (2005) The metabolic syndrome. Lancet, 365, 1415-1428.
2. Lim, S., Shin, H., Song, J.H., et al,. (2011) Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care, 34, 1323-1328.
3. Isomaa, B., Almgren, P., Tuomi, T., et al,. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-689.
4. Mottillo, S., Filion, K.B., Genest, J., et al,. (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American College of Cardiology, 56, 1113-1132.
5. Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al,. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735-2752.
6. Sattar, N., Preiss, D., Murray, H.M., et al,. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375, 735-742.
7. Saito, Y., Yamada, N., Teramoto, T., et al,. (2002) A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis, 162, 373-379.
8. Yokote, K., Bujo, H., Hanaoka, H., et al,. (2008) Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 201, 345-352.
9. Nomura, S., Shouzu, A., Omoto, S., et al,. (2008) Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thrombosis Research, 122, 39-45.
10. Inami, N., Nomura, S., Shouzu, A., et al,. (2007) Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiology of Haemostasis and Thrombosis, 36, 1-8.
11. Choi, S.H., Kim, D.J., Lee, K.E., et al,. (2004) Cut-off value of waist circumference for metabolic syndrome patients in Korean adult population. The Korean Journal of Obesity, 13, 53-60.
12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20, 1183-1197.
13. Wilson, P.W., D'Agostino, R.B., Levy, D., et al,. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837-1847.
14. Khang, Y.H., &, Yun, S.C., (2010) Trends in general and abdominal obesity among Korean adults: findings from 1998, 2001, 2005, and 2007 Korea National Health and Nutrition Examination Surveys. Journal of Korean Medical Science, 25, 1582-1588.
15. Kahn, R., Buse, J., Ferrannini, E., et al,. (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 28, 2289-2304.
16. Yamakawa, T., Takano, T., Tanaka, S., et al,. (2008) Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. Journal of Atherosclerosis and Thrombosis, 15, 269-275.
17. Nomura, S., Shouzu, A., Omoto, S., et al,. (2009) Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagulation & Fibrinolysis, 20, 440-447.
18. Matsubara, T., Naruse, K., Arakawa, T., et al,. (2012) Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study. Journal of Cardiology, 60, 389-394.
19. Fujioka, Y., Fukuda, A., Ishida, T., et al,. (2011) Pitavastatin reduces elevated IL-18 levels in Japanese subjects with hypercholesterolemia: sub-analysis of Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN). Journal of Atherosclerosis and Thrombosis, 18, 8-15.
20. Chinen, I., Shimabukuro, M., Yamakawa, K., et al,. (2007) Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology, 148, 160-165.
21. Whitehead, J.P., Richards, A.A., Hickman, I.J., et al,. (2006) Adiponectin-a key adipokine in the metabolic syndrome. Diabetes, Obesity & Metabolism, 8, 264-280.
22. Kizer, J.R., Arnold, A.M., Benkeser, D., et al,. (2012) Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care, 35, 415-423.
23. Ridker, P.M., Danielson, E., Fonseca, F.A., et al,. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359, 2195-2207.
24. Gastaldelli, A., &, Basta, G., (2010) Ectopic fat and cardiovascular disease: what is the link? Nutrition, Metabolism & Cardiovascular Diseases, 20, 481-490.
25. Wajchenberg, B.L., (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews, 21, 697-738.